Clin Exp Rheumatol: Characteristics and Risk Factors for Pulmonary Embolism in Patients with Systemic Lupus

Pulmonary embolism (PE) is life-threatening, but there is little evidence to assess PE risk factors in patients with systemic lupus erythematosus (SLE)The study aims to explore the characteristics and risk factors of PE in SLE patientsusing the Beijing Concord Hospital Information System, a case-control study of SLE patients who combined PE from January 2012 to December 2018 was conducted, with age, sex and admission time matching sLE patients without PE as a control group of 1:3The risk factors of PE in SLE patients were discussed using multi-logistic regression analysisidentified 90 patients diagnosed as PE from 6,994 hospitalized SLE patients and selected 257 matching controls (only 2 controls in 13 cases)The average annual incidence of PE in inpatient SLE patients from 2012 to 2018 was 1.29% (95% CI: 1.15%-1.42%), higher than all hospitalized patients (0.347% and 95% CI: 0.34%-0.354%)In the case group, the majority were female (74/90; 82.2%), with an average pre-PE SLE duration of 3.04 to 2.16 years, with a mortality rate of 8.9%Multi-factor analysis shows that BMI 25kg/m2 (OR 8.221 (3.125-21.622), p 0.001), SLE disease course 1.5 years (OR 3.815 (1 .824-7.97), p.001, low-albuminemia (OR 2.8 (1.226-6.397), p.015, hsCRP, 3mg / L (OR 3.744 (1.693-8.276), p.001,aPL-positive (OR 10.57 (4.389-25.46), p 0.0 The maximum dose of glucocorticoids is an important independent risk factor for PE in Patients with SLEThe use of hydroxychloroquine (OR 0.262 (0.117-0.589), p-0.001) is a protective factor in PE in SLE patientsthis study provides general population-based evidence of an increased risk of PE in SLE patientsBe vigilant in preventing this serious, preventable complication, especially within a few months of SLE diagnosis